Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Cryo-EM Reveals Integrin-Mediated TGF-β Activation without Release from Latent TGF-β.

Campbell MG, Cormier A, Ito S, Seed RI, Bondesson AJ, Lou J, Marks JD, Baron JL, Cheng Y, Nishimura SL.

Cell. 2020 Feb 6;180(3):490-501.e16. doi: 10.1016/j.cell.2019.12.030. Epub 2020 Jan 16.

PMID:
31955848
2.

The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA.

Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD.

Toxins (Basel). 2019 Dec 20;12(1). pii: E9. doi: 10.3390/toxins12010009.

3.

Botulinum Neurotoxins (BoNTs)-Antibody and Vaccine.

Lou J, Marks JD.

Toxins (Basel). 2018 Nov 26;10(12). pii: E495. doi: 10.3390/toxins10120495.

4.

Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.

Takasaka N, Seed RI, Cormier A, Bondesson AJ, Lou J, Elattma A, Ito S, Yanagisawa H, Hashimoto M, Ma R, Levine MD, Publicover J, Potts R, Jespersen JM, Campbell MG, Conrad F, Marks JD, Cheng Y, Baron JL, Nishimura SL.

JCI Insight. 2018 Oct 18;3(20). pii: 122591. doi: 10.1172/jci.insight.122591.

5.

Cryo-EM structure of the αvβ8 integrin reveals a mechanism for stabilizing integrin extension.

Cormier A, Campbell MG, Ito S, Wu S, Lou J, Marks J, Baron JL, Nishimura SL, Cheng Y.

Nat Struct Mol Biol. 2018 Aug;25(8):698-704. doi: 10.1038/s41594-018-0093-x. Epub 2018 Jul 30.

6.

A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.

Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD.

Toxins (Basel). 2018 Mar 1;10(3). pii: E105. doi: 10.3390/toxins10030105.

7.

A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.

Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD.

Toxins (Basel). 2018 Feb 15;10(2). pii: E84. doi: 10.3390/toxins10020084.

8.

A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.

Fan Y, Garcia-Rodriguez C, Lou J, Wen W, Conrad F, Zhai W, Smith TJ, Smith LA, Marks JD.

PLoS One. 2017 Mar 21;12(3):e0174187. doi: 10.1371/journal.pone.0174187. eCollection 2017.

9.

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.

Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS.

J Infect Dis. 2016 May 15;213(10):1606-14. doi: 10.1093/infdis/jiv770. Epub 2016 Mar 1.

10.

Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.

Fan Y, Dong J, Lou J, Wen W, Conrad F, Geren IN, Garcia-Rodriguez C, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

Toxins (Basel). 2015 Aug 26;7(9):3405-23. doi: 10.3390/toxins7093405.

11.

Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.

Fan Y, Geren IN, Dong J, Lou J, Wen W, Conrad F, Smith TJ, Smith LA, Ho M, Pires-Alves M, Wilson BA, Marks JD.

PLoS One. 2015 Aug 14;10(8):e0135306. doi: 10.1371/journal.pone.0135306. eCollection 2015.

12.

TGF-β-Dependent Dendritic Cell Chemokinesis in Murine Models of Airway Disease.

Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Ma R, Murray LA, Tsui P, Lou J, Marks JD, Baron JL, Krummel MF, Nishimura SL.

J Immunol. 2015 Aug 1;195(3):1182-90. doi: 10.4049/jimmunol.1500348. Epub 2015 Jun 24.

13.

Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 Promoter.

Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, Nishimura SL.

J Biol Chem. 2015 Jun 5;290(23):14717-28. doi: 10.1074/jbc.M114.630368. Epub 2015 Apr 27.

14.

Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Jenko KL, Zhang Y, Kostenko Y, Fan Y, Garcia-Rodriguez C, Lou J, Marks JD, Varnum SM.

Analyst. 2014 Oct 21;139(20):5093-102. doi: 10.1039/c4an01270d. Epub 2014 Aug 12.

15.

Selective targeting of TGF-β activation to treat fibroinflammatory airway disease.

Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL.

Sci Transl Med. 2014 Jun 18;6(241):241ra79. doi: 10.1126/scitranslmed.3008074.

16.

Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A.

FEBS Lett. 2014 Apr 2;588(7):1087-93. doi: 10.1016/j.febslet.2014.02.034. Epub 2014 Feb 25.

17.

RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.

Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S.

Talanta. 2013 Dec 15;117:273-80. doi: 10.1016/j.talanta.2013.09.012. Epub 2013 Sep 13.

18.

Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E.

Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T.

Biochem J. 2013 Jul 1;453(1):37-47. doi: 10.1042/BJ20130391.

PMID:
23621114
19.

Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays.

Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM.

Anal Biochem. 2012 Nov 15;430(2):185-92. doi: 10.1016/j.ab.2012.08.021. Epub 2012 Aug 27.

20.

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD.

Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7.

Supplemental Content

Loading ...
Support Center